Skip to main content

Table 1 Clinical and ultrasound data for the patients in DAS28CRP-remission > 1 year obtained through a treat-to-target steered strategy

From: Using a DAS28-CRP-steered treat-to-target strategy does not eliminate subclinical inflammation as assessed by ultrasonography in rheumatoid arthritis patients in longstanding clinical remission

  All patients (n = 87) csDMARD group (n = 45) bDMARD group (n = 42) Difference between groups (p values)
Age (years) 61 (25–82) 64 (31–82) 57 (25–82) 0.14
Female gender 66% 62% 69% 0.50
Disease duration (years) 10 (1–54) 6 (1–44) 13 (0–2) < 0.001
Positive rheumatoid factor 61% 56% 67% 0.29
Positive anti-CCP 67% 56% 79% 0.02
Erosive disease 66% 51% 81% 0.003
Number of current DMARDs 1 (0–3) 1 (0–3) 1 (0–1) 0.003
Clinical assessment
 Swollen joint count (0–28) 0 (0–2) 0 (0–2) 0 (0–2) 0.71
 Tender joint count (0–28) 0 (0–1) 0 (0–1) 0 (0–1) 0.60
 CRP (mg/L) 5 (1–26) 4 (1–13) 5 (4–26) < 0.001
 DAS28CRP 1.8 (1.1–2.5) 1.7 (1.1–2.4) 1.9 (1.6–2.5) 0.002
 HAQ (0–3) 0.125 (0–1.625) 0 (0–0.875) 0.31 (0–1.625) 0.002
 VAS Global (mm) (0–100) 13 (0–67) 10 (0–45) 15 (0–67) 0.16
 ACR-EULAR* 1.6 (0–7.7) 1.4 (0–5.3) 1.8 (0–7.7) 0.35
 ACR-EULAR-remission* 77% 76% 79% 0.74
 SDAI 2.1 (0.3–8.2) 1.6 (0.3–6.1) 2.8 (0.5–8.2) 0.05
 SDAI-remission 75% 76% 74% 0.85
Ultrasound assessment
 Grey-scale sum score (0–72) 6 (0–19) 4 (1–18) 6.5 (0–19) 0.71
 Doppler sum score (0–72) 0 (0–12) 0 (0–12) 0 (0–7) 1.00
 Grey-scale sum score (MCP2–5 and wrist) (0–30) 3 (0–18) 3 (0–18) 3 (0–12) 0.25
 Doppler sum score (MCP2–5 and wrist) (0–30) 0 (0–12) 0 (0–12) 0 (0–5) 0.84
  1. Values are given as median (range) and percentage. Comparison between groups by Mann-Whitney’s test and Pearson chi-square with p < 0.05 considered significant
  2. DMARDs disease-modifying anti-rheumatic drugs, CRP C-reactive protein, HAQ Health Assessment Questionnaire, VAS visual analogue scale
  3. *Patients in ACR-EULAR Boolean-remission are identical to patients in CDAI-remission